Huilin Tang1,2, Guangyao Li3, Ying Zhao3, Fei Wang4, Emily W Gower5, Luwen Shi3, Tiansheng Wang1,5. 1. Department of Pharmacy, Peking University Third Hospital, Beijing, China. 2. Department of Epidemiology, Richard M. Fairbanks School of Public Health, Indiana University, Indianapolis, Indiana. 3. Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China. 4. Department of Pharmacy Practice, University of Connecticut, School of Pharmacy, Storrs, Connecticut. 5. Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Abstract
AIM: To assess the comparative effects of glucose-lowering drugs (GLDs) on the risk of diabetic retinopathy (DR) in patients with type 2 diabetes mellitus (T2DM). METHODS: We systematically searched Cochrane Central Register of Controlled Trials, PUBMED and EMBASE from inception to January 17, 2017 to identify randomized controlled trials (RCTs) that reported DR events among T2DM patients receiving any GLD. Random-effects pairwise and network meta-analyses were performed to calculate odds ratios (ORs) with 95% confidence intervals (CIs). RESULTS: A total of 37 independent RCTs with 1806 DR events among 100 928 patients with T2DM were included. The mean duration of diabetes was 8.7 years and mean baseline HbA1c was 8.2% (SD, 0.5%). Our network meta-analysis found that DPP-4i (OR, 1.20; 95% CI, 0.87-1.65), GLP-1RA (OR, 1.19; 95% CI, 0.94-1.52) and SGLT2 inhibitors (OR, 0.79; 95% CI, 0.49-1.28) were not associated with a higher risk of DR than placebo; however, a significantly increased risk of DR was associated with DPP-4i in the pairwise meta-analysis (OR, 1.27; 95% CI, 1.05-1.53). Sulfonylureas, on the other hand, were associated with a significantly increased risk of DR compared to placebo (OR, 1.67; 95% CI, 1.01-2.76). CONCLUSIONS: Current evidence indicates that the association between DPP-4i, GLP-1RA or SGLT2 inhibitors and risk of DR remains uncertain in patients with T2DM. Some evidence suggests that sulfonylureas may be associated with increased risk of DR. However, given that DR events were not systematically assessed, these effects should be explored further in large-scale, well-designed studies.
AIM: To assess the comparative effects of glucose-lowering drugs (GLDs) on the risk of diabetic retinopathy (DR) in patients with type 2 diabetes mellitus (T2DM). METHODS: We systematically searched Cochrane Central Register of Controlled Trials, PUBMED and EMBASE from inception to January 17, 2017 to identify randomized controlled trials (RCTs) that reported DR events among T2DM patients receiving any GLD. Random-effects pairwise and network meta-analyses were performed to calculate odds ratios (ORs) with 95% confidence intervals (CIs). RESULTS: A total of 37 independent RCTs with 1806 DR events among 100 928 patients with T2DM were included. The mean duration of diabetes was 8.7 years and mean baseline HbA1c was 8.2% (SD, 0.5%). Our network meta-analysis found that DPP-4i (OR, 1.20; 95% CI, 0.87-1.65), GLP-1RA (OR, 1.19; 95% CI, 0.94-1.52) and SGLT2 inhibitors (OR, 0.79; 95% CI, 0.49-1.28) were not associated with a higher risk of DR than placebo; however, a significantly increased risk of DR was associated with DPP-4i in the pairwise meta-analysis (OR, 1.27; 95% CI, 1.05-1.53). Sulfonylureas, on the other hand, were associated with a significantly increased risk of DR compared to placebo (OR, 1.67; 95% CI, 1.01-2.76). CONCLUSIONS: Current evidence indicates that the association between DPP-4i, GLP-1RA or SGLT2 inhibitors and risk of DR remains uncertain in patients with T2DM. Some evidence suggests that sulfonylureas may be associated with increased risk of DR. However, given that DR events were not systematically assessed, these effects should be explored further in large-scale, well-designed studies.
Authors: Patricia Bogdanov; Hugo Ramos; Marta Valeri; Anna Deàs-Just; Jordi Huerta; Rafael Simó; Cristina Hernández Journal: Biomedicines Date: 2022-02-16
Authors: Lakshini Y Herat; Vance B Matthews; P Elizabeth Rakoczy; Revathy Carnagarin; Markus Schlaich Journal: Int J Endocrinol Date: 2018-07-05 Impact factor: 3.257
Authors: Ricardo Raúl Robles-Rivera; José Alberto Castellanos-González; Cecilia Olvera-Montaño; Raúl Alonso Flores-Martin; Ana Karen López-Contreras; Diana Esperanza Arevalo-Simental; Ernesto Germán Cardona-Muñoz; Luis Miguel Roman-Pintos; Adolfo Daniel Rodríguez-Carrizalez Journal: Oxid Med Cell Longev Date: 2020-03-11 Impact factor: 6.543
Authors: Zaynab Ahmad Mouhammad; Rupali Vohra; Anna Horwitz; Anna-Sophie Thein; Jens Rovelt; Barbara Cvenkel; Pete A Williams; Augusto Azuara-Blanco; Miriam Kolko Journal: Front Neurosci Date: 2022-02-21 Impact factor: 4.677
Authors: Benedetta Maria Bonora; Mattia Albiero; Mario Luca Morieri; Roberta Cappellari; Francesco Ivan Amendolagine; Marta Mazzucato; Alberto Zambon; Elisabetta Iori; Angelo Avogaro; Gian Paolo Fadini Journal: Diabetologia Date: 2021-08-09 Impact factor: 10.122
Authors: Virginia Bellido; Julia Martínez; Fernando Calvo; Aida Villarroel; Edurne Lecumberri; Juan Moreno; Carlos Morillas; Silvia Rodrigo; Aitziber Izarra; Albert Lecube Journal: Diabetes Ther Date: 2022-03-25 Impact factor: 3.595